Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib

Detalles Bibliográficos
Autores principales: Zhou, A, Knoche, E M, Engle, E K, Fisher, D A C, Oh, S T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635189/
https://www.ncbi.nlm.nih.gov/pubmed/26430722
http://dx.doi.org/10.1038/bcj.2015.77
_version_ 1782399473861787648
author Zhou, A
Knoche, E M
Engle, E K
Fisher, D A C
Oh, S T
author_facet Zhou, A
Knoche, E M
Engle, E K
Fisher, D A C
Oh, S T
author_sort Zhou, A
collection PubMed
description
format Online
Article
Text
id pubmed-4635189
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46351892015-11-25 Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib Zhou, A Knoche, E M Engle, E K Fisher, D A C Oh, S T Blood Cancer J Letter to the Editor Nature Publishing Group 2015-10 2015-10-02 /pmc/articles/PMC4635189/ /pubmed/26430722 http://dx.doi.org/10.1038/bcj.2015.77 Text en Copyright © 2015 Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Letter to the Editor
Zhou, A
Knoche, E M
Engle, E K
Fisher, D A C
Oh, S T
Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
title Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
title_full Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
title_fullStr Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
title_full_unstemmed Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
title_short Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
title_sort concomitant jak2 v617f-positive polycythemia vera and bcr-abl-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635189/
https://www.ncbi.nlm.nih.gov/pubmed/26430722
http://dx.doi.org/10.1038/bcj.2015.77
work_keys_str_mv AT zhoua concomitantjak2v617fpositivepolycythemiaveraandbcrablpositivechronicmyelogenousleukemiatreatedwithruxolitinibanddasatinib
AT knocheem concomitantjak2v617fpositivepolycythemiaveraandbcrablpositivechronicmyelogenousleukemiatreatedwithruxolitinibanddasatinib
AT engleek concomitantjak2v617fpositivepolycythemiaveraandbcrablpositivechronicmyelogenousleukemiatreatedwithruxolitinibanddasatinib
AT fisherdac concomitantjak2v617fpositivepolycythemiaveraandbcrablpositivechronicmyelogenousleukemiatreatedwithruxolitinibanddasatinib
AT ohst concomitantjak2v617fpositivepolycythemiaveraandbcrablpositivechronicmyelogenousleukemiatreatedwithruxolitinibanddasatinib

Ejemplares similares